Novavax Approved by CDC as an Additional COVID-19 Vaccine for Adolescents
The CDC recently approved Novavax’s COVID-19 vaccine to be used as another primary series option for adolescents ages 12 through 17. This recommendation follows the FDA’s emergency use authorization for the vaccine for this age group.
Novavax uses protein subunit technology, the same technology used in the Influenza and Whooping Cough vaccines, to help the immune system respond to the virus in the future. Learn more.